Authors:
Fang, JY
Metter, EJ
Landis, P
Chan, DW
Morrell, CH
Carter, HB
Citation: Jy. Fang et al., Low levels of prostate-specific antigen predict long-term risk of prostatecancer: Results from the Baltimore Longitudinal Study of Aging, UROLOGY, 58(3), 2001, pp. 411-416
Citation: Hb. Carter, Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria - Editorial comment, UROLOGY, 58(3), 2001, pp. 424-424
Citation: Ji. Epstein et al., Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1C disease, J UROL, 166(5), 2001, pp. 1688-1691
Authors:
Nelson, WG
Simons, JW
Mikhak, B
Chang, JF
DeMarzo, AM
Carducci, MA
Kim, M
Weber, CE
Baccala, AA
Goeman, MA
Clift, SM
Ando, DG
Levitsky, HI
Cohen, LK
Sanda, MG
Mulligan, RC
Partin, AW
Carter, HB
Piantadosi, S
Marshall, FF
Citation: Wg. Nelson et al., Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies, CANC CHEMOT, 46, 2000, pp. S67-S72
Authors:
Ross, KS
Carter, HB
Pearson, JD
Guess, HA
Citation: Ks. Ross et al., Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection, J AM MED A, 284(11), 2000, pp. 1399-1405
Citation: Hb. Carter, A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: The only rational approach for men 50 years old and older, UROLOGY, 55(6), 2000, pp. 796-799
Authors:
Goldschlag, B
Afzal, N
Carter, HB
Fleisher, LA
Citation: B. Goldschlag et al., Is preoperative donation of autologous blood rational for radical retropubic prostatectomy?, J UROL, 164(6), 2000, pp. 1968-1972
Authors:
Harman, SM
Metter, EJ
Blackman, MR
Landis, PK
Carter, HB
Citation: Sm. Harman et al., Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostatecancer, J CLIN END, 85(11), 2000, pp. 4258-4265
Citation: Hb. Carter et Jd. Pearson, Prostate-specific antigen testing for early diagnosis of prostate cancer: Formulation of guidelines, UROLOGY, 54(5), 1999, pp. 780-786
Citation: Ji. Epstein et al., Prostate cancer sampled on sextant needle biopsy: Significance of cancer on multiple cores from different areas of the prostate, UROLOGY, 54(2), 1999, pp. 291-294
Citation: Hb. Carter et al., Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease, UROLOGY, 53(1), 1999, pp. 126-130
Authors:
Epstein, JI
Walsh, PC
Akingba, G
Carter, HB
Citation: Ji. Epstein et al., The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer, J UROL, 162(5), 1999, pp. 1649-1652
Citation: Hb. Carter, Prostate specific antigen variation in patients without clinically evidentprostate cancer - Comment, J UROL, 162(4), 1999, pp. 1313-1313
Citation: Hb. Carter, Serial prostate specific antigen screening for prostate cancer: A computermodel evaluates competing strategies - Comment, J UROL, 162(3), 1999, pp. 748-748
Authors:
Simons, JW
Mikhak, B
Chang, JF
DeMarzo, AM
Carducci, MA
Lim, M
Weber, CE
Baccala, AA
Goemann, MA
Clift, SM
Ando, DG
Levitsky, HI
Cohen, LK
Sanda, MG
Mulligan, RC
Partin, AW
Carter, HB
Piantadosi, S
Marshall, FF
Nelson, WG
Citation: Jw. Simons et al., Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer, CANCER RES, 59(20), 1999, pp. 5160-5168